Abstract: The application discloses multimeric assemblies packaging one or more active component and their use to carry out nucleic acid regulation or gene editing.

Abstract: Disclosed am protein switches that can sequester bioactive peptides and/or binding domains, holding them in an inactive (“off”) state, until combined with a second designed polypeptide called die key, which induces a conformational change that activates (“on”) the bioactive peptide or binding domain only when the protein switch components are co-localized when bound to their targets, components of such protein switches, and their use.

Abstract: The present disclosure provides a chimeric polypeptide comprising a helical bundle which comprises between about two and about seven alpha-helices and a bioactive peptide, wherein one or more of the alpha helices form one or more inter-helix hydrogen bonds and comprise at least one phosphorylation site and wherein the bioactive peptide is conformationally placed inside the helical bundle so that the bioactive peptide is not activated or exposed. The disclosure also provides a nucleotide sequence encoding the chimeric polypeptide, a vector comprising the nucleotide sequence, a cell comprising the nucleotide sequence, and method of making, using, or designing the chimeric polypeptide.

Abstract: Disclosed are protein switches that can sequester bioactive peptides and/or binding domains, holding them in an inactive (“off”) state, until combined with a second designed polypeptide called the key, which induces a conformational change that activates (“on”) the bioactive peptide or binding domain only when the protein switch components are co/localized when bound to their targets, components of such protein switches, and their use.

Abstract: Conditionally active receptor agonists that, when activated, bind to IL-2 receptor ?c heterodimer (IL-2R?c), IL-4 receptor ?c heterodimer (IL-4R?c), or IL-13 receptor a subunit (IL˜13 R?) are disclosed, as are components of the conditionally active receptor agonists and methods for using the conditionally active receptor agonists.

Abstract: Synthetic nanostructures, polypeptides that are useful, for example, in making synthetic nanostructures, and methods for using synthetic nanostructures are disclosed herein.

Abstract: The present disclosure related to chimeric antigen receptors (CARs) comprising immunoglobulin (Ig) derived spacers, e.g., hinge or loop regions, fragments thereof, or combinations thereof. Ig derived spacer confers improved properties to the CARs, e.g., increased cytokine release with respect the CARs with spacers not derived from hinge regions and fragments thereof, loop regions from constant domains and fragments thereof, and combinations thereof. Also provided are cells expressing CARs comprising Ig derived spacers regions and methods to use the CARs to treat diseases or disorders, e.g., cancer. Some of the disclosed Ig derived spacers are fragments from, e.g., IgA1, IgA2, IgD, IgE, IgG1, IgG2, IgG3, IgG4, or IgM. In some aspects, the disclosed Ig derived spacers are derived from non-human immunoglobulins, e.g., mouse immunoglobulins such IgG2A. Other Ig derived spacer disclosed are modular constructs comprising several concatenated Ig hinges or fragments thereof.

Abstract: The present disclosure relates to EGFR-derived polypeptides containing short juxtamembrane sequences, nucleic acids encoding them, and methods of using them to improve cell surface expression of truncated EGFR markers.

Abstract: Disclosed are protein switches that can sequester bioactive peptides and/or binding domains, holding them in an inactive (“off”) state, until combined with a second designed polypeptide called the key, which induces a conformational change that activates (“on”) the bioactive peptide or binding domain, components of such protein switches, and their use.

Abstract: Disclosed are protein switches that can sequester bioactive peptides and/or binding domains, holding them in an inactive (“off”) state, until combined with a second designed polypeptide called the key, which induces a conformational change that activates (“on”) the bioactive peptide or binding domain, components of such protein switches, and their use.

Abstract: Disclosed are protein switches that can sequester bioactive peptides and/or binding domains, holding them in an inactive (“off”) state, until combined with a second designed polypeptide called the key, which induces a conformational change that activates (“on”) the bioactive peptide or binding domain, components of such protein switches, and their use.

Abstract: The application discloses multimeric assemblies packaging one or more active component and their use to carry out nucleic acid regulation or gene editing.

Abstract: The present invention provides methods for multiplex assembly of oligonucleotides.